Fisher & Paykel Healthcare Corporation Limited · NZX:FPH
Fisher & Paykel Healthcare — Shareholder Meeting (August 2017)
41 slides from Fisher & Paykel Healthcare's shareholder meeting presentation, Aug 24, 2017
Slide 1: Annual Shareholders' Meeting
Annual S Fisher & Paykel HEALTHCARE
Slide 2: Tony Carter, Chairman
Tony Carter, Chairman Fisher & Paykel HEALTHCARE
Slide 3: Your Board
Your Board Michael Daniell Lindsay Gillanders Pip Greenwood Geraldine McBride Arthur Morris Donal O’Dwyer Scott St John Fisher& Paykel HEALTHCARE
Slide 4: Agenda
Agenda * Chair’s Address * Managing Director and Chief Executive Officer’s Review * Financial Statements * Resolutions *« Voting * General Questions Fisher & Paykel HEALTHCARE
Slide 5: Global presence: sales, distribution and manufacturing
© Direct Sales Distributed sales with FPH staff Germany | | Norway © Distribution Centres © Manufacturing Facilities shinai sweden Netherlands Finlanc olaium Enaland canado Scotland Norther Weland = Necharinind YG) || 0 —__+¢ ireland e e Turkey ee Wates e Tense ’ South Korea $ . Japan b Portugal = >
Slide 6: Impact of Changing Demographics
Impact of Changing Demographics e Population age and weight both increasing 100 US population 65 years+ to grow ~80% 90 over next 20 years 80 US males 60 - 74 years, average weight increased 60 0.4 kg/year since 1960 50 60% of US healthcare cost is after age “0 65 years 30 20 Developing markets incr
Slide 7: FY2017 Financial Results
FY2017 Financial Results Record Operating Revenue nz$894.4m Record Net Profit after Tax Nz$169.2™ 110% 1 18% Fisher & Paykel HEALTHCARE
Slide 8: Your Board
Your Board Michael Daniell Lindsay Gillanders Pip Greenwood Geraldine McBride Arthur Morris Donal O’Dwyer Scott St John Fisher& Paykel HEALTHCARE
Slide 9: Tony Carter, Chairman
Tony Carter, Chairman Fisher & Paykel HEALTHCARE
Slide 10: For personal use only
FisheréPaykel HEALTHCARE
Slide 11: Lewis Gradon, Managing Director and CEO
Lewis Gradon, Managing Director and CEO Fisher & Paykel HEALTHCARE
Slide 12: Product Group Revenue
For personal use only Product Group Revenue Hospital OF OPERATING REVENUE NZ$500M Homecare Distributed and Other OF OPERATING REVENUE HEALTHCARE
Slide 13: For personal use only
Fisher & Paykel HEALTHCARE
Slide 14: For personal use only
Fisher &Paykel HEALTHCARE
Slide 15: For personal use only
Fisher &Paykel HEALTHCARE
Slide 16: For personal use only
For personal use only
Slide 17: For personal use only
ykel Pay HEALTHCARE Fisher&
Slide 18: For personal use only
ir personall use only Fisher& Paykel HEALTHCARE
Slide 19: For personal use only
g 6) 2 = o 2 a} ic HEALTHCARE Ajuo osn feuosled
Slide 20: Growth opportunity
For personal use only Growth opportunity Hospital 8M+ currently 7OM+ potential Homecare 3M+ currently 100M+ potential Fisheré.Paykel HEALTHCARE
Slide 21: Nasal High Flow clinical papers published annually
Nasal High Flow clinical papers published annually 180 160 140 120 100 80 60 40 2000 2002 2004 2006 2008 2010 2012 2014 2016 —Adult —Neonatal & Paediatric Fisher & Paykel HEALTHCARE
Slide 22: For personal use only
For personal use only
Slide 23: For personal use only
Fisher & Paykel HEALTHCARE
Slide 24: For personal use only
To be replaced with AKL pic For personal use only
Slide 25: For personal use only
Fisher & Paykel HEALTHCARE
Slide 26: FY2018 Outlook
FY2018 Outlook Full Year Expect at NZD:USD exchange rate of ~0.725 for the balance of the year Operating Revenue Approaching NZ$1 billion Net Profit after Tax ~NZ$180 to $190 million First Half Expect at current exchange rates Operating Revenue ~NZ$460 million Net Profit after Tax ~NZ$80 million Fis
Slide 27: For personal use only
Fisher & Paykel HEALTHCARE
Slide 28: Tony Carter, Chairman
Tony Carter, Chairman Fisher & Paykel HEALTHCARE
Slide 29: Lindsay Gillanders
Lindsay Gillanders Fisher & Paykel HEALTHCARE
Slide 30: Financial Statements
Financial Statements * Opportunity for shareholders to ask any questions specifically on the financial statements, the auditor’s report or the company’s 2017 annual report. ¢« There will be an opportunity to ask any general questions once all items on the agenda have been considered. it receives the
Slide 31: Resolutions
Resolutions * Re-election of Directors * Election of Director ¢ Directors’ Remuneration ¢ Auditor’s Remuneration * Issue of Performance Share Rights * Issue of Options Fisher & Paykel HEALTHCARE
Slide 32: Resolution 1: Re-election of Tony Carter
Resolution 1: Re-election of Tony Carter That Tony Carter, who retires by rotation and, being eligible, offers himself for re-election, be re-elected as a director of the Company. Fisher &Paykel HEALTHCARE
Slide 33: Resolution 2: Re-election of Geraldine McBride
Resolution 2: Re-election of Geraldine McBride That Geraldine McBride, who retires by rotation and, being eligible, offers herself for re-election, be re-elected as a director of the Company. Fisher &Paykel HEALTHCARE
Slide 34: Resolution 3: Election of Pip Greenwood
Resolution 3: Election of Pip Greenwood That Pip Greenwood, who, being eligible, offers herself for election, be appointed as a director of the Company. Fisher &Paykel HEALTHCARE
Slide 35: Resolution 4: Directors' Remuneration
Resolution 4: Directors’ Remuneration That the maximum aggregate annual remuneration payable to non-executive Directors be increased by NZ$100,000 from NZ$950,000 to NZ$1,050,000, such sum to be divided amongst the non-executive Directors in such manner as the Directors see fit. Fisher & Paykel HEAL
Slide 36: Resolution 5: Auditor's Remuneration
Resolution 5: Auditor’s Remuneration That the Directors be authorised to fix the fees and expenses of PwC as the Company’s auditor. Fisher & Paykel HEALTHCARE
Slide 37: Resolution 6: Issue of Performance Share Rights
Resolution 6: Issue of Performance Share Rights That approval be given for the issue of up to 50,000 performance share rights under the Fisher & Paykel Healthcare Performance Share Rights Plan to Mr Lewis Gradon, Managing Director and Chief Executive Officer of the Company. Fisher &Paykel HEALTHCARE
Slide 38: Resolution 7: Issue of Options
Resolution 7: Issue of Options That approval be given for the issue of up to 150,000 options under the Fisher & Paykel Healthcare 2003 Share Option Plan to Mr Lewis Gradon, Managing Director and Chief Executive Officer of the Company. Fisher &Paykel HEALTHCARE
Slide 39: Voting
Voting yee * In respect of each resolution, please tick the “for”, “against” or “abstain” box. * Once you have completed your voting, please place your vote in a ballot box. * Please raise your hand if you require a pen. ¢« Results will be announced to NZX and ASX as soon as they are available. Fish
Slide 40: Questions?
Questions? Fisher & Paykel HEALTHCARE
Slide 41: Annual Shareholders' Meeting
Annual S Fisher & Paykel HEALTHCARE
Fisher & Paykel Healthcare — Shareholder Meeting (August 2017) on 6ix